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Abstract
Summary Vitamin K mediates the synthesis of proteins
regulating bone metabolism. We have tested whether high
vitamin K2 intake promotes bone mineral density and bone
strength. Results showed that K2 improved BMC and
femoral neck width, but not DXA-BMD. Hence high
vitamin K2 intake may contribute to preventing postmen-
opausal bone loss.
Introduction Vitamin K is involved in the synthesis of
several proteins in bone. The importance of K vitamins for
optimal bone health has been suggested by population-
based studies, but intervention studies with DXA-BMD as a
clinical endpoint have shown contradicting results. Unlike
BMC, DXA-BMD does not take into account the geometry
(size, thickness) of bone, which has an independent contri-
bution to bone strength and fracture risk. Here we have tested
whether BMC and femoral neck width are affected by high
vitamin K intake.
Methods A randomized clinical intervention study among
325 postmenopausal women receiving either placebo or
45 mg/day of vitamin K2 (MK-4, menatetrenone) during
three years. BMC and hip geometry were assessed by DXA.
Bone strength indices were calculated from DXA-BMD,
femoral neck width (FNW) and hip axis length (HAL).
Results K2 did not affect the DXA-BMD, but BMC and the
FNW had increased relative to placebo. In the K2-treated
group hip bone strength remained unchanged during the 3-
year intervention period, whereas in the placebo group bone
strength decreased significantly.
Conclusions Vitamin K2 helps maintaining bone strength at
the site of the femoral neck in postmenopausal women by
improving BMC and FNW, whereas it has little effect on
DXA-BMD.
Keywords Bonemineralcontent.Femoralneckstrength.
Fracturerisk.Menaquinone.Osteoporosis.VitaminK
Introduction
Since the discovery of osteocalcin, the vitamin K-depen-
dent protein synthesized by bone tissue, attempts have been
made to correlate bone vitamin K status with bone strength.
The way in which these variables were measured varied in
different studies. Obviously, the best way to assess bone
strength is monitoring fracture incidence in a large study
cohort over a long period of time. Unfortunately, this
method is expensive and time consuming. Therefore, most
authors have used bone mineral density as measured by
DXA (DXA-BMD) as a surrogate marker for bone strength.
A disadvantage of this technique is that it gives the amount
of calcium per area, but does not take into account the three
dimensions of the bone [1]. Findingreliable markers for
bone vitamin K status turned out to be even more difficult.
Dietary vitamin K may occur in different forms: K1 (also
known as phylloquinone) and K2, which is a group name
for a series of related compounds also known as menaqui-
nones [2]. The various menaquinones differ structurally in
the length of their isoprenyl side chain, which may contain
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nine residues in menaquinones-9 (MK-9). Still higher
menaquinones have been described, but are increasingly
rare in the diet. Dietary K1 originates mainly from green,
leafy vegetables, whereas menaquinones are produced by
bacteria and are mostly found in fermented foods such as
cheese and the Japanese food natto (fermented soy beans)
[3, 4]. Synthetic forms of vitamin K available in food
supplements or pharmaceutical preparations are K1 and
MK-4, recently also the natural MK-7 has become
available. The recommended daily intake of vitamin K
(all forms) is between 100 and 120 μg/day, but this value is
based on the hepatic vitamin K requirement for blood
clotting factor synthesis. The requirements of other tissues
have not yet been defined, but are probably higher.
In 1984, Hart and coworkers described a case-control
study in which patients with femur neck fractures had lower
circulating vitamin K1 concentrations than age- and sex-
matched controls [5]. In a second study from the same
authors it was found that subjects with low serum vitamin
K1 concentrations had a lower DXA-BMD than those with
normal or high serum vitamin K1 [6]. A potential bias in
these studies is that low circulating vitamin K may be a
marker for general poor nutritional status and that low
DXA-BMD and increased fracture risk are associated with
the combined deficiency of essential minerals, vitamins and
proteins rather than with vitamin K alone.
Others have published population-based studies in which
an inverse correlation was found between fracture risk and
vitamin K1 intake [7, 8]. It was found that the association
between vitamin K1 intake and fracture risk was much
stronger than that between vitamin K1 intake and DXA-
BMD [9]. A drawback of these studies is that no attempts
were made to also monitor vitamin K2 intake. Although in
the western society K2 forms only 10–20% of the total
vitamin K intake [3, 4], it is absorbed from the food matrix
much better than K1 and may cover 50% of the total
vitamin K absorbed. Moreover, it has been demonstrated
that vitamin K2 rather than K1 is preferentially taken up by
extrahepatic tissues such as bone and arteries [10]. Hence
also vitamin K1 intake seems to be a questionable marker
for bone vitamin K status.
Possibly the best marker available today is circulating
undercarboxylated osteocalcin (ucOC). Either the absolute
concentration, the ratio between ucOC and total osteocal-
cin, or the ratio between ucOC and carboxylated osteo-
calcin (cOC) are used in the literature. The group of
Delmas [11–13] and Luukinen et al. [14] reported a
number of independent studies suggesting a strongly
increased fracture risk in populations with elevated serum
ucOC; later studies by the French group [15] and others [9,
16] showed that ucOC was inversely associated with DXA-
BMD. It is at least remarkable that in all approaches,
associations between vitamin K status and fracture risk were
demonstrated more readily than those between K status and
DXA-BMD.
In a supplementation study with vitamin K1 alone no
effect on DXA-BMD was observed during a 2-year
treatment with 10 mg/day [17]. In another study from the
same group, however, a synergistic effect of 1 mg/day of
K1 with minerals and vitamin D [18] was found. In this
study the rate of bone loss in postmenopausal women was
reported to be 35% lower in the presence of minerals and
vitamins K1 and D as compared to the group receiving
minerals and vitamin D without vitamin K. A number of
Japanese studies reported variable effects of vitamin K2
alone, but substantial beneficial effects if combined with
vitamin D [19].
It has been reported by many different authors that in the
healthy population serum osteocalcin is incompletely
carboxylated, which is indicative for poor vitamin K status
of bone [11, 14, 16, 20]. Based on our present knowledge
of vitamin K-dependent proteins, it must be expected that
non-carboxylated osteocalcin is not functional. Since the
molecular function of osteocalcin has remained unclear thus
far, we do not know whether it contributes to bone strength
at all. From transgenic osteocalcin-deficient mice, we know
that osteocalcin contributes to regulating the form and the
dimensions of bone [21]. This may also be important for
humans.
The importance of bone geometry for bone strength is
rapidly gaining interest [22–26]. Although DXA-BMD is
still the determinant most generally used in the clinical
evaluation of hip fracture risk, it has been stipulated that its
uncritical use may lead to size-related artifacts in the
estimation of bone strength and in the identification of
fracture risk [27]. As was mentioned by Heaney [28], the
ultimate concern in studying bone status is bone strength.
Holding other variables constant, strength will increase
both as bone mass increases and as bone size increases.
When estimating bone strength, two strategies to also
compensate for the dimensions of bone have been pro-
posed. First, it is encouraged that densitometric compar-
isons between groups are based on bone mineral content
(BMC) rather than on DXA-BMD [28]. Second, bone
dimensions are used as independent determinants for bone
strength. Important geometric parameters are the hip axis
length (HAL) and the femoral neck width (FNW). Patients
with low DXA-BMD or after experiencing a hip fracture
had an increased FNW, suggesting an attempt to compen-
sate for the increased fracture risk at this critical site [26].
On the other hand, it seems obvious that at comparable
DXA-BMD a larger FNW will positively contribute to bone
strength. In this way it is understandable that also and
increase of BMC may contribute to bone strength, although
it should be reminded that it is not the mass per se but the
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importance of combining bone geometry with DXA-BMD
for expressing bone strength and fracture risk was realized
by Karlamangla et al., who developed mathematical
equations for calculating indices for compression strength,
bending strength, and impact strength of the femoral neck
[29]. In these equations, DXA-BMD is combined with
HAL, FNW, height and body weight. We have used the
same equations to analyse the data from a placebo-
controlled intervention trial in which we compared the
effects of vitamin K2 on DXA-BMD and bone strength
indices in postmenopausal women, who were recruited
from the apparently healthy population and thus represent
the large group of free living elderly subjects. Additional or
synergistic effects of calcium and vitamin D were not
included in the design of our study.
Subjects and methods
Subjects
The study was designed for apparently healthy, non-osteo-
porotic women. Participants were recruited by local news-
papers.Inclusioncriteriawerefemalegender,agebetween55
and 75 years at intake, Caucasian race, apparently healthy, at
least 2 years postmenopausal and willingness to sign
informed consent. Exclusion criteria were: a history of
metabolic bone disease(s) or recent bone fractures (less than
one year), low bone density (T-score < −2.5), ovariectomy,
hysterectomy, oral anticoagulant treatment, hormone replace-
ment therapy, treatment with bisphosphonates, calcitonin,
prednisone, heparin, or vitamin K-containing vitamin con-
centrates and food supplements. Also subjects who had
received an investigational new drug within the last
12 months were excluded from the trial. In total 325
womenmetthecriteriaandwererandomizedintoourstudy.
The participants were pre-stratified according to age: 105 in
the age of 55–65 years, and 220 in the age of 65–75 years.
The study protocol was approved by the University
Hospital medical ethics committee.
Masking
Participants were identified by a single randomization
number according to the randomization schedule generated
by the University Hospital Pharmacy using a computer-
generated random permutation procedure in the software
package SPSS. Participants were randomly assigned to
treatment with either 45 mg/day of MK-4 (menatetrenone,
EISAI Co, Tokyo, Japan) or placebo, and compliance with
treatment was decided from pill counts during home visits.
The daily dose of MK-4 was given in three capsules of
15 mg each, which had to be taken at three time points
spread over the day, preferably after the meal. The
participant randomization codes were allocated sequentially
in the order in which the participants were enrolled. After
completion of all analyses the randomization code was
disclosed to the investigator.
Measurements
The clinical end points chosen to evaluate the effect of the
study treatment on bone were bone mineral density (DXA-
BMD), bone mineral content (BMC) and bone strength
indices of the femoral neck. DXA-BMD and BMC were
measured at baseline and after 1, 2 and 3 years of treatment
by dual energy X-ray absorptiometry (DXA) at the site of
the left total hip and femoral neck, as well as the vertebrae
(L2-L4) using a Hologic QDR 4500-A (Waltham MA,
USA). The in vivo precision (CV) after repeated measure-
ments in 10 healthy adults (30–40 years old) was 0.85% for
the spine and 0.78% for the femur neck in short term (one
day interval) and 1.03% and 0.98% in long term (one-year
interval) precision measurements. The long-term precision
of FNWassessment was 1.53%. At each time point, standing
height and body weight were determined with standardized
equipment and the body mass index (BMI) was calculated as
theweightin kilogramsdividedby the square of theheight in
meters. The daily calcium intake was assessed using a
validated food frequency questionnaire. Indices for com-
pression strength (CSI), bending strength (BSI) and impact
strength (ISI) at the site of the femoral neck were calculated
from the mean femoral neck width (FNW) and hip axis
length (HAL), together with height, weight and femoral neck
DXA-BMD as described by Karlamangla et al. [29]. The
mean FNW was obtained from the 1.5 cm wide femoral
neck region of interest (area (cm
2)/1.5 (cm)). The HAL
reflects the distance along the femoral neck axis from the
lateral margin at the base of the greater trochanter to the
inner pelvic brim. The equations used were:
CSI ¼ BMD   FNW ðÞ =weight
BSI ¼ BMD   FNW2  
HAL   weight ðÞ
ISI ¼ BMD   FNW   HAL ðÞ = height   weight ðÞ
Sample collection
Fasting blood was taken and 2-h fasting urine was collected at
baseline and after 3, 6, 12 and 36 months of treatment. After
blood was taken, it was allowed to clot at room temperature
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3,000 rpm, during 15 minutes. It was subdivided in small
aliquots and kept at −80°C until use. Urine was collected as
the second morning void after an overnight fast.
Biochemical measurements
In serum the following markers were tested, all based on
enzyme immuno assays (EIA): total osteocalcin (t-OC,
BioSource Europe SA); under-carboxylated osteocalcin
(uc-OC) and carboxylated osteocalcin (c-OC) both
obtained from Takara Shuzo Co Ltd., Shiga, Japan; bone-
specific alkaline phosphatase (BAP, Alkphase B, Quidel/
Metra Biosystems San Diego, CA, USA); N-telopeptides of
type I collagen (sNTX, Osteomark sNTx, Ostex Interna-
tional, Inc., Seattle, WA, USA) and 25-Hydroxy vitamin D
(25-OH D, OCTEIA 25-hydroxy vitamin D, IDS, UK).
In the urine we measured free deoxypyridinoline by
using an enzyme immunoassay (DPD, Quidel/Metra Bio-
systems). Urinary calcium (Ca) and creatinine (creat) were
assessed according to standard methods. Dpd and Ca were
corrected for the urinary creat concentration.
Statistics
The required numbers of participants in both age groups
were assessed using separate power analyses (power of
90% and a significance level of 0.05). In the younger age
group it was assumed that in the placebo group the mean
bone loss is approximately 1.5% (4.5% in 3 years). The
lowest detectable effect was set at an improvement of 30%
(=3.15% bone loss after 3 years). Taking into account a
drop-out frequency of 12% per year this group should
consist of at least 76 subjects. In the older age group the
mean bone loss was assumed to amount 1% per year (3% in
3 years). With a lowest detectable effect of 30% (=2.1%
bone loss in 3 years) and a drop-out frequency of 19% per
year, the minimal size of this group is 218 subjects.
Statistical analysis was performed using the statistical
package SPSS (SPSS Corp, Chicago, IL). The calculations
are based on the intention-to-treat principle. Drop-outs were
included in the analyses, with the last data available in all
subsequent measuring points. All follow-up measurements
were related to the baseline values and the proportional
changes were calculated for each subject. Differences
between and within the different groups were assessed with
the unpaired and paired Student’s t-test, respectively. All
data are given as mean values ±SE. The linear regression
model was used to investigate the effect of treatment after
adjustment for potential confounders. Change of FNW,
HAL and bone strength indices after 3 years of treatment
were used as dependent variables and age and BMI as
independent variables.
Results
Baseline measurements and follow-up
Three hundred fifty-one women were recruited for the study,
26ofwhomwereexcludedbeforerandomizationfordifferent
reasons. After randomization there were 161 women receiv-
ing MK-4 and 164 women receiving placebo. The MK-4
group consisted of 54 women younger than 65 years of age
and 107 women older than 65 years of age; in the placebo
group these numbers were 51 and 113, respectively. The
baseline characteristics of all participants in the placebo and
MK-4 group are given in Table 1. No significant differences
were found between both groups. However, when compar-
ing the two age groups there was an age-related increase in
weight and BMI and an age-related decrease in height
(Table 2). DXA-BMD and BMC in the older age group were
significantly lower at the site of the femoral neck, but not at
the total hip and spine. From all serum markers for bone
metabolism only BAP was higher in the older age group
(borderline significant). Although there was an age-related
decrease in serum vitamin D concentration, all participants
had levels which were within the normal range at baseline
(Tables 1 and 2) and at all subsequent measurements (data
not shown). Urinary DPD/creat was markedly lower in the
older age group compared to the younger group.
After 3 years 257 women had completed the study: 133
women in the MK-4 group and 124 women in the placebo
group. In total 68 women stopped during the study. This was
21% of the total. The largest group of participants (n=30)
stopped during the first 3 months of the trial. The most
important reasonsfordiscontinuationinthis timeperiodwere
various health problems (n=18), low DXA-BMD (n=17),
lack of motivation (n=10) and complaints about the capsules
(n=9). Subjects who stopped because of low DXA-BMD did
so after consultation during the trial with their general
practitioner; there were two complaints about the capsules
in the MK-4 group and seven in the placebo group. Two
participants died during the trial: one brain tumor and one
cerebrovascular accident. Both casualties were in the placebo
group. In total, 36 negative or positive side effects were
mentioned by the participants. In the MK-4 group 16 women
experienced negative effects and four experienced positive
effects of the capsules; in the placebo group the numbers
were 15 and one, respectively. The most frequent negative
effects were gain of weight and gastro-intestinal complaints.
However, there was no difference in total numbers of
complaints between the MK-4 and the placebo group.
Effect of MK-4 supplementation
Effects on serum markers (if detectable) were maximal
after 12 months of treatment, with no further increase of
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have plotted the changes of bone markers in serum during
the first year. As was to be expected, a statistically
significant effect of vitamin K treatment was observed on
the serum concentrations of cOC and ucOC. The markers
for bone formation (tOC and BAP) were also significantly
higher in the MK-4 group as compared to the placebo
one. No effect was observed on markers for bone
resorption, or on DXA-BMD at any of the sites measured
(Fig. 2a). Also urinary calcium excretion was not affected
by MK-4 treatment (data not shown). It turned out that in
the MK-4 group the BMC of the femoral neck decreased
at a significantly lower rate than in the placebo one
(Fig. 2b), and that this effect was paralleled by a significant
increase in the femoral neck width, suggesting bone accrual
at this critical site (Fig. 2c). The hip axis length (HAL)
seemed to slightly increase with age in an MK-4 indepen-
dent manner. From the DXA-BMD, the FNW and the HAL
we have calculated the various indices for strength of the
femur neck, and it resulted that MK-4 had a significant
effect on all three indices (Fig. 2d). Notably the bending
strength remained almost constant after the three years of
intervention.
Using a linear regression model, we have tested the
statistical significance of the MK-4 induced effects. As is
shown in Table 3, the differences in FNW, CSI, BSI and ISI
between the MK-4 and placebo group were significant,
both before and after adjustment for age and BMI. The
effects on BMC, FNW and bone strength indices were
observed for both age groups. As is shown in Fig. 3 the loss
of bone strength in the MK-4 supplemented group was
almost negligible in the group of 65 years and older.
Discussion
InthispaperwedemonstratethatthemaineffectofvitaminK2
on bone in the hip is an increase of the femoral neck BMC
and width, resulting in maintenance of the calculated bone
strength even at decreasing DXA-BMD after the menopause.
Table 1 Baseline characteris-
tics of all participants subdi-
vided according to treatment
Only the BMC and the impact
strength index of the femoral
neck in the MK-4 group were
slightly higher than in the
placebo one. This difference is
accounted for by expressing
MK-4-induced changes as a
percentage of the baseline val-
ues. All data are given ± SE.
Placebo n=164 MK-4 n=161 P-value
Anthropomorphic variables:
Age (years) 66.0±0.5 65.9±0.4 0.9
Years since menopause 17.7±0.7 17.2±0.6 0.6
Weight (kg) 71.8±1.0 70.3±0.9 0.3
Height (cm) 162±0.5 161±0.5 0.2
BMI (kg/m
2) 27.3±0.3 27.1±0.4 0.7
Calcium intake (mg/day) 811±26 870±32 0.1
Non-smoking (%) 87 87 1.0
Bone density characteristics:
DXA-BMD (g/cm
2) of: femoral neck 0.688±0.007 0.706±0.008 0.1
Total hip 0.842±0.009 0.861±0.008 0.1
Lumbar L2-L4 0.931±0.012 0.929±0.013 0.9
BMC (g) of: femoral neck 3.54±0.04 3.65±0.04 0.06
Total hip 30.6±0.43 31.4±0.39 0.2
Lumbar L2-L4 43.1±0.72 42.4±0.76 0.6
Hip geometry:
Mean FNW (cm) 3.43±0.02 3.45±0.017 0.4
HAL (cm) 11.6±0.07 11.7±0.06 0.2
Bone strength indices:
CSI (g/kg.m) 3.41±0.055 3.52±0.052 0.1
BSI (g/kg.m) 1.00±0.017 1.04±0.017 0.2
ISI (g/kg.m) 0.24±0.004 0.26±0.004 0.03
Serum markers for bone metabolism:
c-OC (ng/mL) 6.1±0.2 6.2±0.2 1.0
uc-OC (ng/mL) 3.3±0.2 3.3±0.2 0.4
t-OC (ng/mL) 13.2±0.4 13.2±0.5 0.7
BAP (ng/mL) 23.1±0.7 23.6±0.8 0.2
NTX (nM) 10.8±0.2 10.7±0.3 0.5
25-OH D (nM) 67.2±2.3 72.3±2.6 0.09
Urine markers for bone metabolism:
Creatinine (mmol/L) 3.5±0.3 3.6±0.2 1.0
DPD / creat (μmol/mol) 7.4±0.2 7.5±0.2 0.7
Calcium / creat (mol/mol) 0.29±0.02 0.29±0.01 0.7
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therapy with other food supplements (calcium, vitamin D) or
drugs (bisphosphonates) with known effects on also DXA-
BMD. The potential synergism between K2 and other sup-
plements/drugs, however, requires further investigation.
In the literature there are many indications that vitamin
K contributes to the maintenance of optimal bone strength.
Besides various population-based studies and a number of
clinical intervention trials investigating the effects of
increased vitamin K intake, it has also been reported that
subjects receiving vitamin K antagonists (oral anticoagulant
therapy) have lower DXA-BMD and increased fracture risk
[30–32]. Also experimental animals developed osteopenia
upon treatment with the vitamin K antagonist warfarin [33].
On the other hand we must conclude, however, that in
intervention trials the reported effects on DXA-BMD of
vitamin K alone were small; most studies published thus far
indicate that only in combination with calcium and vitamin
D, vitamin K has a synergistic effect on DXA-BMD [18,
19, 34]. Osteocalcin is the most abundant vitamin K-
dependent protein in bone, and the phenotype of transgenic
osteocalcin-deficient mice suggests that it is primarily
involved in the correct arrangement of hydroxyapatite
crystals and in structuring the correct dimensions of bone
[21]. Both factors may contribute to the total bone strength.
Hence studies in which DXA-BMD is the only clinical
endpoint do not give conclusive evidence on bone strength.
If, for instance, the femoral neck DXA-BMD remains
constant but increases in width the bone will become
stronger and more resistant to fracture. Therefore, we have
used mathematical procedures for calculating three indices
for bone strength at the site of the femoral neck.
Despite the very high dose of MK-4 used in the present
trial, no effect was found on the DXA-BMD of the femoral
neck, the total hip or the lumbar spine. On the other hand,
significant positive effects were observed both on the
femoral neck BMC and width. The relation between
DXA-BMD, BMC and FNW can be seen from the formula:
DXA-BMD=BMC/area, where FNW is one of the dimen-
sions of the surface area. In case FNW is increasing, the
Table 2 Baseline characteris-
tics of participants subdivided
according to age
The differences in all age-relat-
ed variables were highly signif-
icant. All data are given±SE.
Age 55–65 n=105 Age 65–75 n=220 P-value
Anthropomorphic variables:
Age (years) 59.0±0.3 69.3±0.2
Years since menopause 9.7±0.5 21.2±0.4
Weight (kg) 67.4±1.0 72.8±0.8 0.0001
Height (cm) 163±0.6 161±0.4 0.003
BMI (kg/m
2) 25.4±0.4 28.1±0.3 0.0001
Calcium intake (mg/day) 816±34 858±27 0.4
Non-smoking (%) 88 87 0.9
Bone density characteristics:
DXA-BMD (g/cm
2) of: femoral neck 0.716±0.010 0.689±0.006 0.02
Total hip 0.871±0.012 0.842±0.007 0.03
Lumbar L2-L4 0.940±0.015 0.925±0.011 0.4
BMC (g) of: femoral neck 3.69±0.06 3.55±0.03 0.02
Total hip 31.4±0.6 30.7±0.3 0.3
Lumbar L2-L4 44.0±0.9 42.1±0.6 0.1
Hip geometry:
Mean FNW (cm): 3.44±0.022 3.44±0.016 0.9
HAL (cm): 11.8±0.08 11.6±0.06 0.03
Bone strength indices:
CSI (g/kg m): 3.75±0.068 3.31±0.039 0.0001
BSI (g/kg m): 1.09±0.022 0.98±0.013 0.0001
ISI (g/kg m): 0.27±0.005 0.24±0.003 0.0001
Serum markers for bone metabolism:
c-OC (ng/mL) 5.9±0.2 6.3±0.2 0.2
uc-OC (ng/mL) 3.3±0.2 3.2±0.1 0.8
t-OC (ng/mL) 13.9±0.6 12.8±0.4 0.1
BAP (ng/mL) 21.8±0.8 24.1±0.7 0.05
NTX (nM) 11.0±0.3 10.6±0.2 0.2
25-OH D (nM) 76.5±2.7 66.3±2.3 0.005
Urine markers for bone metabolism:
creatinine (mmol/L) 3.5±0.3 3.6±0.2 0.8
DPD / creat (nmol/mmol) 8.2±0.2 7.1±0.2 0.0001
Calcium / creat (mmol/mmol) 0.29±0.02 0.29±0.01 0.9
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increase too. In case BMC remains constant, the DXA-
BMD values will decrease. In case FNW increases and
BMC increases adequately, DXA-BMD remains constant,
with a concomitant increase of bone strength. The impor-
tance of the FNW for the calculated bone strength is
obvious from the equations for all three bone strength
indices. Our results showed that during the entire interven-
tion period there was no or very little decrease in bone
strength in the K2 treated group, whereas there was
substantial loss of bone strength in the placebo one. The
favourable effect was found both in the young postmeno-
pausal group (55–65 years old) as well as in the older group
(65–75 years old). Since together with vitamin D and
calcium vitamin K was also reported to have a positive
effect on DXA-BMD it might even be speculated that the
combination of these supplements will result in an increase
of bone strength. After we obtained these data, we re-
analysed previous studies from our lab, and it turned out
that vitamin K1 had only little or no effect on the FNW. It
should be pointed out, however, that the doses used in these
studies were 1 mg/day and 10 mg/day, which is consider-
ably lower than the 45 mg/day used in the present study.
The first question that may be raised is whether the very
high dose of vitamin K used in our study is required to
obtain the observed effect. The present recommendations
for vitamin K intake vary between 90 and 120 micrograms
per day, and in a dose of 45 milligrams per day the vitamin
is used as a drug rather than as a food supplement. It should
be realized, however, that MK-4 has a very short biological
halflife time (1–2 h), which is the reason why it was given
three times daily in a dose of 15 mg per helping. Even at
this regimen its short halflife will result in fluctuating K2
serum levels, which may explain the requirement of a high
dose. At this time no data are available on the efficacy of
MK-4 at lower doses, for instance in the range between
100–500 micrograms per day. A possible alternative to
MK-4 might be using MK-7, the K2 vitamin most
abundantly found in the Japanese food natto (fermented
soy beans). MK-7 has probably a comparable effect as MK-
4[ 35], but it has a halflife in the circulation of 3 days,
resulting in more constant plasma levels and accumulation
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Fig.1 EffectofMK-4 on
markers for bone metabolism
during the first year of treat-
ment. Bone formation markers
are presented in graphs a–d
(cOC, ucOC, tOC and BAP,
respectively) andboneresorption
markers in graph E and F (NTX
and DPD/creat respectively).
Closed symbols: MK-4; open
symbols: placebo. Error bars
represent SE. Significance of
differences MK-4 compared to
placebo: #: p<0.05; ##: p<0.005
Osteoporos Int (2007) 18:963–972 969in the blood and various tissues. Therefore, MK-7 is the most
logical choice for use as a low-dose food supplement,
because even at low intake relatively high blood and tissue
levels can be obtained. Clinical trials in which the efficacy of
MK-7 is tested are, however, lacking at this time. From our
study it is not clear whether the high MK-4 regimen will
increase vertebral bone strength in a similar way as observed
for the DXA-derived femoral neck bone strength. To our
knowledge no reliable formulas are available for calculating
vertebral compression strength, the most important strength
index for the vertebrae. However, the substantial and
significanteffectofMK-4onthelumbarspineBMCwarrants
more elaborate studies in which the effect on vertebral
fracture risk is investigated. A substantial risk reduction for
vertebral fractures by long-term MK-4 treatment has also
been reported by a number of Japanese studies [36, 37].
Another question that needs to be answered is why K2
has a much more pronounced effect than K1. One reason
may be the different doses used: 45 mg/day for MK-4 and
1–10 mg/day for K1. Based on our present knowledge, all
three doses are an excess; it seems not unlikely, therefore,
that there is a qualitative difference between K1 and K2.
The only difference between both vitamins is the aliphatic
side chain, which does not influence the coenzyme
function, but which does affect the distribution of vitamin
K over the lipoproteins in the blood, and the transport to
and absorption by the various tissues. It has been
demonstrated in human volunteers that both K1 and K2
are transported to the liver via triglycerides, but that only
K2 vitamins (both MK-4 and MK-7) are incorporated into
the LDL fraction for transport to extrahepatic tissues [39]. It
is not surprising, therefore, that in animal experiments it
Fig. 2 Effects of MK-4 on bone after 3 years of treatment. All data are
expressed as a percentage of the respective baseline values. Graph A
shows the data of DXA-BMD of the femoral neck (DXA-BMDFN),
total hip (DXA-BMDtotalhip) and lumbar spine (DXA-BMDLS);
graph B shows the BMC of the femoral neck (BMCFN), total hip
(BMCtotalhip) and lumbar spine (BMCLS); graph C shows the
femoral neck width (FNW) and hip axis length (HAL) and graph D
shows the indices of the compression strength (CSI), bending strength
(BSI) and impact strength (ISI). Open bars: placebo; hatched bars:
MK-4. Error bars represent SE. Significance of change from baseline:
*: p<0.05, **: p<0.005; significance of difference MK-4 compared to
placebo: #: p<0.05, ##: p<0.005
Table 3 Effect of MK-4 treatment on geometrical variables
Unadjusted adjusted mean difference (SE) p Mean difference(SE) p
FNW (%) +1.30 (0.50) 0.01 +1.34 (0.50) 0.009
HAL (%) − 0.25 (0.26) 0.3 +0.23 (0.22) 0.9
CSI (%) +2.26 (0.77) 0.004 +2.03 (0.76) 0.008
BSI (%) +3.80 (1.2) 0.002 +3.83 (1.2) 0.001
ISI (%) +1.98 (0.82) 0.02 +1.72 (0.79) 0.03
The increase/decrease of each variable was calculated as a percentage from its baseline value. The differences between the change in MK-4 group
and that in the placebo group are given. A positive value reflects a more pronounced effect in the MK-4, a negative value reflects a more
pronounced effect in the placebo group. The values are given before and after adjustment for age and BMI, adjusted values are quoted at the
mean values for age and BMI of the total group (age=65.9 years; BMI=27.2 kg/m
2).
970 Osteoporos Int (2007) 18:963–972was found that K1 mainly accumulates in the liver, whereas
MK-4 is far more abundant in other tissues including
pancreas, bone and vessel wall [10]. In that perspective, K2
seems to be the most logical choice for supplementation
because notably bone and arteries (and not the liver) were
reported to have a sub-optimal vitamin K status in the
majority of the healthy population.
A limitation of this study is that it was conducted in non-
osteoporotic women, in whom we tried to decrease bone loss
and to maintain bone strength. Therefore, this study does not
allow conclusions regarding beneficial effects of vitamin K2
on bone quality in women who have been diagnosed with
osteoporosis already. A further limitation is that the study
was exclusively conducted on women, so that no conclu-
sions can be drawn for bone loss in men. A further limitation
of our study was that the DXA-BMD of the spine was
determined only in the postero-anterior (PA) position. This
measurement includes not only the trabecular bone of the
vertebral body, but also a substantial amount of cortical bone
from posterior elements. During ageing, degenerative
changes in the spine such as osteoarthritis or sclerosis of
the endplates may occur. In those cases, PA projection may
result in incorrect interpretation of the DXA-BMD and BMC
values because the observed increase is due to degenerative
changes and is not based on treatment effect. Lateral DXA-
BMD measurements evaluate exclusively the vertebral body,
allowing more sensitive detection of postmenopausal bone
loss or DXA-BMD changes during therapy [38]. At the start
of this study lateral DXA-BMD monitoring, however, was
not yet available for clinical trials in our hospital.
In conclusion we have demonstrated that vitamin K2 is
capable of improving both the BMC and bone geometry at
critical sites, leading to maintenance of the DXA-derived
femoral neck bone strength in postmenopausal women
during a 3-year study period. Even in the very high doses
used in our study, adverse side effects of MK-4 were minor
and not different from the placebo group. Therefore, it
seems desirable to evaluate the cost-benefits of supplement-
ing low dose vitamin K2 to all postmenopausal women. The
optimal dose, the preferred form (MK-4 or MK-7), and
synergistic effects of complementary food supplements
(calcium, vitamin D) or medication (bisphosphonates),
however, require further research.
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